Turnstone, which went public via an $80 million IPO in 2023, ended September 2024 with $45.3 million to hand, which the ...

the multi-group collaboration looked at how cancer cells interact with tumor-infiltrating lymphocytes, a type of T-cell that ...

SAN DIEGO - Turnstone Biologics Corp. (NASDAQ:TSBX), a clinical-stage biotechnology company with a market capitalization of $9.45 million, has announced the discontinuation of its TIDAL-01 clinical ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.

Lunit and SITC collaborate to offer SITC members exclusive access to Lunit SCOPE IO for AI-driven tumor microenvironment ...

Iovance Biotherapeutics (IOVA -0.96%), a small-cap biotech company, has an innovative approach to treating cancer that relies ...

Research has introduced daromun, therapeutic vaccines, and novel combinations for metastatic melanoma, reshaping the ...

Lunit offers free AI biomarker services to SITC researchers for immuno-oncology studies Global researchers gain access to ...

Researchers identify glucose usage as one major divergence betweenT cells expanding in vitro versus those expanding in vivo.

Their oncologists are clamoring for more treatment options for patients who don't respond well to standard care. Amtagvi is ...

A Bay Area biotech is suing its insurance company to cover costs associated with patients allegedly injured during clinical ...